Literature DB >> 26064309

Early diagnosis, treatment and prognosis of epilepsy with continuous spikes and waves during slow sleep.

Qiang Yuan1, Fengtong Li1, Hongping Zhong2.   

Abstract

The study is to investigate the importance of early diagnosis and treatment to the prognosis of epilepsy with continuous spikes and waves during slow sleep (CSWS). A total of 8 cases of CSWS children were followed up for 6 months to 4 years. Retrospective analysis of the clinical and electroencephalographic (EEG) characteristics, treatment and prognosis was performed in these 8 cases. Of the 8 cases of CSWS patients, 5 were males and 3 were females. Epilepsy onset ages were from 3 years and 1 month to 10 years and 6 months. Five cases of the patients were with brain lesions while the other 3 cases appeared normally by imaging detection. After treatment with valproic acid, clonazepam, lamotrigine and hormone for 3 months, clinical symptoms and EEG were improved significantly in 7 cases. Two cases relapsed at 6 months after comprehensive treatment. For atypical early performance of CSWS, early diagnosis and regular treatment could improve the condition of children with seizures and effectively inhibit the epileptic activity with good prognosis.

Entities:  

Keywords:  Epilepsy with continuous spikes and waves during slow sleep; clinical; electroencephalogram; prognosis; treatment

Year:  2015        PMID: 26064309      PMCID: PMC4443143     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

1.  Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases.

Authors:  Alec Aeby; Nathalie Poznanski; Denis Verheulpen; Catherine Wetzburger; Patrick Van Bogaert
Journal:  Epilepsia       Date:  2005-12       Impact factor: 5.864

Review 2.  Alternative approaches to conventional antiepileptic drugs in the management of paediatric epilepsy.

Authors:  R Kneen; R E Appleton
Journal:  Arch Dis Child       Date:  2006-11       Impact factor: 3.791

3.  Corticosteroids for the treatment of Landau-kleffner syndrome and continuous spike-wave discharge during sleep.

Authors:  D Barry Sinclair; Thomas J Snyder
Journal:  Pediatr Neurol       Date:  2005-05       Impact factor: 3.372

Review 4.  Corticosteroids in the management of the paediatric epilepsies.

Authors:  R Gupta; R Appleton
Journal:  Arch Dis Child       Date:  2005-04       Impact factor: 3.791

5.  Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy.

Authors: 
Journal:  Epilepsia       Date:  1989 Jul-Aug       Impact factor: 5.864

6.  Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells.

Authors:  David A Hess; Louisa Wirthlin; Timothy P Craft; Phillip E Herrbrich; Sarah A Hohm; Ryan Lahey; William C Eades; Michael H Creer; Jan A Nolta
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

7.  Is ESES/CSWS a strictly age-related disorder?

Authors:  P Mariotti; G Della Marca; L Iuvone; G F Mennuni; M Guazzelli; S Marchetti; S Mazza
Journal:  Clin Neurophysiol       Date:  2000-03       Impact factor: 3.708

8.  Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep.

Authors:  Marga Buzatu; Christine Bulteau; Cécilia Altuzarra; Olivier Dulac; Patrick Van Bogaert
Journal:  Epilepsia       Date:  2009-08       Impact factor: 5.864

9.  Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.

Authors:  Daniel J Pearce; David Taussig; Catherine Simpson; Kirsty Allen; Ama Z Rohatiner; T Andrew Lister; Dominique Bonnet
Journal:  Stem Cells       Date:  2005 Jun-Jul       Impact factor: 6.277

10.  Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.

Authors:  A Lugli; G Iezzi; I Hostettler; M G Muraro; V Mele; L Tornillo; V Carafa; G Spagnoli; L Terracciano; I Zlobec
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.